Cancer News and Research

Latest Cancer News and Research

Nordion presents TheraSphere Phase II trial results against liver metastases at SIR meeting

Nordion Inc., a leading provider of products and services to the global health science market, today shared results from the first multi-site, Phase II clinical trial to evaluate TheraSphere® for treatment of metastatic liver cancer.

29 Mar 2011

CINJ scientist receives University of Texas award for cancer therapeutic research

In recognition of efforts made in cancer therapeutic research, Joseph R. Bertino, MD, chief scientific officer at The Cancer Institute of New Jersey, has been honored with The Jeffrey A. Gottlieb Memorial Award sponsored by The University of Texas MD Anderson Cancer Center. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

29 Mar 2011

People with arthritis can benefit from exercise

An estimated 50 million adults in the United States suffer from arthritis. According to the Centers for Disease Control, one of the best ways to combat the onset of arthritis as well as to control pain and improve function is through exercise.

29 Mar 2011

FDA approves Medtronic's Protecta implantable defibrillators

Medtronic, Inc. today announced U.S. Food and Drug Administration approval of the Protecta portfolio of implantable cardioverter-defibrillators and cardiac resynchronization therapy-defibrillators.

29 Mar 2011

CPRIT awards $36.7 million grant to UT Southwestern for cancer research

The Cancer Prevention and Research Institute of Texas has awarded more than $36.7 million in new grants to investigators at UT Southwestern Medical Center to support cancer-related projects and to recruit pre-eminent cancer investigators.

29 Mar 2011

Drugs for prevention of breast cancer

According to an international panel of cancer experts, women at high risk of developing breast cancer should be given preventative drugs. The experts write in the Lancet Oncology adding, drugs such as tamoxifen could reduce the chances of developing breast cancer. They suggest that this would be something similar to prescribing statins to patients at risk of heart disease. But tamoxifen has been linked with womb cancer, blood clots and stroke.

28 Mar 2011

Prostate cancer updates

A Hunter-based prostate cancer support group says ground-breaking research by the University of Newcastle will help save many lives in the region. This new work has found patients with localized advanced prostate cancer can double their chances of survival by undertaking hormone therapy in combination with radiology treatment. This comes from a 10 year trial, coordinated by the University's Professor Jim Debnam.

28 Mar 2011

Angioplasty procedures have minimal risk

Understanding that angioplasty—a medical treatment used by interventional radiologists to widen the veins in the neck and chest to improve blood flow—is safe may encourage additional studies for its use as a treatment option for individuals with multiple sclerosis, say researchers at the Society of Interventional Radiology's 36th Annual Scientific Meeting in Chicago, Ill.

28 Mar 2011

Poll finds proposal to cut Planned Parenthood funding deepens gender gap

Meanwhile, in a second story, Alaska Sen. Lisa Murkowski says the funding fight is far from over.

28 Mar 2011

IMRIS sells IMRISNV to University of Utah Hospital

IMRIS Inc. today announced the sale of IMRISNV to University of Utah Hospital in Salt Lake City, Utah.

28 Mar 2011

Bionovo initiates enrollment in Menerba Phase 1 clinical trial for menopausal hot flushes

Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced that enrollment has started for the Phase 1 clinical trial testing the safety of two doses of Menerba in postmenopausal women for the treatment of menopausal hot flushes (study # MF101-008), also known as "menopausal hot flashes."

28 Mar 2011

How is the health care safety net faring?

News outlets examine the safety net from varying vantage points to see how it is holding up in advance of the health law's coverage expansions and during difficult economic times.

28 Mar 2011

Concord Medical fourth quarter total net revenues increase 30.1% to RMB112.9 million

Concord Medical Services Holdings Limited, the operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced its unaudited consolidated financial results for the fourth quarter and fiscal year ended December 31, 2010.

28 Mar 2011

Everist Genomics announces global launch of OncoDefender-CRC colorectal cancer assay

Everist Genomics today announced the worldwide commercial availability of its OncoDefender-CRC colorectal cancer assay, the first and only molecular prognostic test capable of accurately predicting the risk of recurrence of cancer in patients previously treated with surgical resection of a Stage I/II colon cancer tumor or Stage I rectal cancer tumor.

28 Mar 2011

WaferGen launches SmartChip Human microRNA Panel V2 for gene expression profiling

WaferGen Biosystems, Inc., a leading developer of state-of-the-art genomic analysis systems, today announced the launch of its industry-leading SmartChip Human microRNA Panel V2 for gene expression profiling on the SmartChip Real-Time PCR System.

28 Mar 2011

Dosing commences in Phase I clinical study of GenSpera's G-202 at Cancer Therapy & Research Center

GenSpera, Inc. announced that the first patient was dosed in the ongoing Phase I clinical study of its chemotherapeutic agent, G-202, at the Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio in San Antonio, Texas.

28 Mar 2011

Phase 2a study of DARA BioSciences KRN5500 in treatment of cancer pain reaches primary end-point

Researchers studying a new medication for neuropathic pain have reported intriguing findings about placebo response versus drug response from a Phase 2a proof-of-concept study. They presented their findings in a poster session at the 2011 International Conference on Accelerating the Development of Enhanced Pain Treatments.

28 Mar 2011

Cancer drug Gleevec may hold promise against scleroderma: Study

A drug approved to treat certain types of cancer has shown promising results in the treatment of patients with scleroderma, according to results from an open-label Phase II trial. While the drug's efficacy must be demonstrated in a Phase III trial, the gold standard for testing a drug, researchers are optimistic that Gleevec- (imatinib) could potentially be a weapon against the chronic connective tissue disease for which a treatment has remained elusive.

28 Mar 2011

MolecularMD and ARIAD collaborate to develop and commercialize CML, ALL diagnostic test

ARIAD Pharmaceuticals, Inc. and MolecularMD Corporation today announced an exclusive collaboration agreement in which MolecularMD will develop and commercialize a companion diagnostic test to identify the T315I mutation of the BCR-ABL gene in patients with chronic myeloid leukemia and Philadelphia positive acute lymphoblastic leukemia.

28 Mar 2011

AVEO to present tivozanib preclinical data, monoclonal antibody pipeline at AACR meeting

AVEO Pharmaceuticals, Inc. today announced that preclinical data on tivozanib, AVEO's lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, and the company's monoclonal antibody pipeline will be presented during poster sessions at the American Association for Cancer Research 102nd Annual Meeting 2011 being held April 2-6, 2011 in Orlando, Fla.

28 Mar 2011

Cancer News and Research

Latest Cancer News and Research

Nordion presents TheraSphere Phase II trial results against liver metastases at SIR meeting

CINJ scientist receives University of Texas award for cancer therapeutic research

People with arthritis can benefit from exercise

FDA approves Medtronic's Protecta implantable defibrillators

CPRIT awards $36.7 million grant to UT Southwestern for cancer research

Drugs for prevention of breast cancer

Prostate cancer updates

Angioplasty procedures have minimal risk

Poll finds proposal to cut Planned Parenthood funding deepens gender gap

IMRIS sells IMRISNV to University of Utah Hospital

Bionovo initiates enrollment in Menerba Phase 1 clinical trial for menopausal hot flushes

How is the health care safety net faring?

Concord Medical fourth quarter total net revenues increase 30.1% to RMB112.9 million

Everist Genomics announces global launch of OncoDefender-CRC colorectal cancer assay

WaferGen launches SmartChip Human microRNA Panel V2 for gene expression profiling

Dosing commences in Phase I clinical study of GenSpera's G-202 at Cancer Therapy & Research Center

Phase 2a study of DARA BioSciences KRN5500 in treatment of cancer pain reaches primary end-point

Cancer drug Gleevec may hold promise against scleroderma: Study

MolecularMD and ARIAD collaborate to develop and commercialize CML, ALL diagnostic test

AVEO to present tivozanib preclinical data, monoclonal antibody pipeline at AACR meeting

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Fourier 80: bringing benchtop NMR systems to the laboratory

How industrial hygiene flow calibration supports defensible exposure data

How electrical engineering ensures accurate calibration and patient safety

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Fourier 80: bringing benchtop NMR systems to the laboratory

How industrial hygiene flow calibration supports defensible exposure data

How electrical engineering ensures accurate calibration and patient safety

Newsletters you may be interested in